

A Phase II Trial of High Dose Interleukin-2 with Recombinant MAGE-A3 Protein Combined with Adjuvant System AS15 in Patients with Unresectable or Metastatic Melanoma

Objective:

- To evaluate the response and safety induced by interleukin-2 and MAGE-A3 vaccine

Eligibility Criteria:

- Unresectable or metastatic melanoma
- Patients must have at least one biopsiable cutaneous, subcutaneous, lymph node lesion, lung or liver lesion
- ECOG performance status of 0-1
- Normal organ function
- No brain metastases
- History of autoimmune disease such as, but not limited to, multiple sclerosis, lupus, rheumatoid arthritis, and inflammatory bowel disease



Procedures:

- Clinic visit every three weeks and admission to hospital for 1 week each cycle for at least 2 cycles
- Vaccine injection every 3 weeks
- Tumor biopsy to be done before starting treatment

Benefits for Patients

- May improve the response rate to interleukin-2
- May help identifying patients who would respond to this treatment

Protocol # 2010-0113

Principal Investigator: Jade Homsy, MD

- Schedule an appointment or make referral online at <http://my.mdanderson.org> or call (713) 563-2000
- For more information about the study, contact Research Nurse: MaryAnne LaFontaine, RN at (713) 794-4105
- For information on related articles or references for this study, visit <http://physicianrelations.org>

THE UNIVERSITY OF TEXAS

**MD Anderson
Cancer Center**

Making Cancer History®